BCR-ABL fusion protein (b3a2) (922-930)

BCR-ABL fusion protein (b3a2) (922-930) is a synthetic peptide fragment that corresponds to a specific amino acid sequence derived from the breakpoint region of the BCR-ABL oncoprotein, a hallmark of the Philadelphia chromosome translocation commonly associated with chronic myeloid leukemia (CML). This peptide encompasses residues 922 to 930 of the b3a2 fusion junction, representing a critical epitope formed by the juxtaposition of BCR and ABL gene sequences. As such, it serves as an important molecular tool for studying the biochemical properties and immunogenic features of the BCR-ABL fusion protein, supporting diverse research applications in cancer biology, molecular diagnostics, and immunological investigations.

Epitope mapping: The b3a2 (922-930) peptide is widely employed in epitope mapping studies to delineate immune recognition sites specific to the BCR-ABL fusion junction. By providing a well-defined antigenic sequence, it enables researchers to identify and characterize T cell or antibody responses directed against the unique neoepitope created by the chromosomal translocation. Such investigations are fundamental for understanding immune surveillance mechanisms in leukemia and for the rational design of immunotherapeutic strategies targeting the fusion protein.

Immunoassay development: As a representative peptide of the BCR-ABL fusion region, this fragment is instrumental in the development and optimization of immunoassays, including ELISA and peptide-MHC multimer assays. Its defined sequence allows for the generation of highly specific reagents to detect and quantify immune responses or circulating antibodies against the BCR-ABL neoantigen in research samples. This application supports the monitoring of disease progression, minimal residual disease, and immunological status in preclinical leukemia models.

T cell functional studies: The peptide serves as a valuable tool in functional assays designed to assess T cell activation, proliferation, and cytokine production in response to the BCR-ABL fusion epitope. By loading antigen-presenting cells with this peptide, researchers can evaluate the specificity and potency of cytotoxic T lymphocytes or helper T cell responses in vitro. These studies are essential for elucidating the mechanisms of antigen-specific immunity and for screening candidate T cell receptors or therapeutic modalities targeting the fusion protein.

Peptide-based vaccine research: Given its unique sequence derived from the oncogenic fusion junction, the b3a2 (922-930) peptide is frequently utilized in preclinical research focused on peptide-based vaccine development. It provides an experimental model for assessing the immunogenicity and safety of synthetic vaccines targeting leukemia-associated antigens. Incorporation of this peptide into vaccine formulations allows researchers to investigate immune priming, antigen processing, and presentation pathways relevant to leukemia immunoprevention.

Analytical and quality control applications: In peptide synthesis and analytical laboratories, the b3a2 (922-930) fragment serves as a reference standard for quality control, assay calibration, and method validation. Its well-characterized sequence and defined biochemical properties enable precise assessment of assay performance, peptide purity, and analytical reproducibility. Such use cases are critical for ensuring the reliability of experimental data in both academic and industrial research settings.

1. Emu oil in combination with other active ingredients for treating skin imperfections

2. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

3. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

4. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

5. Myotropic activity of allatostatins in tenebrionid beetles